Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 22 | 2024 | 227 | 3.750 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 12 | 2025 | 34 | 1.680 |
Why?
|
| Proteomics | 1 | 2024 | 299 | 0.730 |
Why?
|
| Cerebellar Diseases | 1 | 2020 | 9 | 0.620 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 34 | 0.620 |
Why?
|
| Infectious Mononucleosis | 1 | 2020 | 34 | 0.610 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2019 | 18 | 0.610 |
Why?
|
| Biomarkers | 3 | 2024 | 1503 | 0.600 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 28 | 0.600 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 105 | 0.560 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 113 | 0.560 |
Why?
|
| Dystonia | 1 | 2018 | 13 | 0.550 |
Why?
|
| Sjogren's Syndrome | 1 | 2018 | 25 | 0.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 256 | 0.510 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 4 | 2024 | 16 | 0.500 |
Why?
|
| Central Nervous System Diseases | 2 | 2016 | 57 | 0.460 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 7 | 0.450 |
Why?
|
| Etanercept | 1 | 2015 | 33 | 0.450 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 382 | 0.440 |
Why?
|
| Sarcoidosis | 1 | 2015 | 33 | 0.430 |
Why?
|
| Uveitis | 1 | 2015 | 34 | 0.430 |
Why?
|
| White Matter | 3 | 2023 | 138 | 0.420 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 249 | 0.410 |
Why?
|
| Olivary Nucleus | 1 | 2013 | 3 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2015 | 224 | 0.400 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 59 | 0.390 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 39 | 0.390 |
Why?
|
| Positron-Emission Tomography | 4 | 2024 | 233 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 2324 | 0.380 |
Why?
|
| Lymphoma | 1 | 2013 | 101 | 0.380 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 227 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 605 | 0.370 |
Why?
|
| Humans | 41 | 2025 | 65845 | 0.350 |
Why?
|
| Receptors, GABA | 2 | 2024 | 13 | 0.340 |
Why?
|
| Middle Aged | 20 | 2025 | 18501 | 0.340 |
Why?
|
| Adult | 18 | 2025 | 17579 | 0.330 |
Why?
|
| Male | 23 | 2025 | 31410 | 0.320 |
Why?
|
| Quality of Life | 2 | 2023 | 1266 | 0.320 |
Why?
|
| Female | 23 | 2025 | 34425 | 0.290 |
Why?
|
| Pyrimidines | 2 | 2019 | 144 | 0.250 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2739 | 0.250 |
Why?
|
| Vertebral Artery | 1 | 2006 | 29 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2022 | 263 | 0.240 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 993 | 0.230 |
Why?
|
| Immunologic Factors | 3 | 2020 | 108 | 0.230 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 202 | 0.220 |
Why?
|
| Crotonates | 2 | 2025 | 4 | 0.220 |
Why?
|
| Toluidines | 2 | 2025 | 4 | 0.220 |
Why?
|
| Meninges | 1 | 2024 | 11 | 0.210 |
Why?
|
| Alemtuzumab | 4 | 2023 | 11 | 0.170 |
Why?
|
| Cerebellum | 2 | 2019 | 94 | 0.170 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 126 | 0.170 |
Why?
|
| Inflammation | 2 | 2019 | 1198 | 0.170 |
Why?
|
| Dimethyl Fumarate | 1 | 2020 | 8 | 0.160 |
Why?
|
| Familial Mediterranean Fever | 1 | 2020 | 9 | 0.160 |
Why?
|
| Phenotype | 1 | 2024 | 1236 | 0.160 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2020 | 20 | 0.160 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 472 | 0.160 |
Why?
|
| Cytokines | 1 | 2024 | 965 | 0.160 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 60 | 0.160 |
Why?
|
| Pyroptosis | 1 | 2020 | 38 | 0.150 |
Why?
|
| Microglia | 2 | 2023 | 254 | 0.150 |
Why?
|
| Cysteine | 1 | 2020 | 108 | 0.150 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 116 | 0.150 |
Why?
|
| Young Adult | 6 | 2020 | 4883 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2019 | 104 | 0.140 |
Why?
|
| Movement | 1 | 2020 | 166 | 0.140 |
Why?
|
| Seizures | 1 | 2019 | 141 | 0.140 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.140 |
Why?
|
| Salivary Glands, Minor | 1 | 2018 | 3 | 0.140 |
Why?
|
| Primary Dysautonomias | 1 | 2018 | 6 | 0.140 |
Why?
|
| Alcoholism | 1 | 2021 | 329 | 0.140 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 8 | 0.140 |
Why?
|
| Neuralgia | 1 | 2018 | 21 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 345 | 0.140 |
Why?
|
| Sensation Disorders | 1 | 2018 | 23 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 679 | 0.140 |
Why?
|
| Syncope | 1 | 2018 | 42 | 0.140 |
Why?
|
| Antibodies, Antinuclear | 1 | 2018 | 41 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 329 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 488 | 0.130 |
Why?
|
| Natalizumab | 2 | 2014 | 11 | 0.130 |
Why?
|
| Migraine Disorders | 1 | 2018 | 46 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 58 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2020 | 2651 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2019 | 170 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2016 | 122 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.130 |
Why?
|
| Aged | 10 | 2024 | 15147 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Rituximab | 2 | 2014 | 89 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2017 | 85 | 0.130 |
Why?
|
| Basigin | 1 | 2016 | 3 | 0.120 |
Why?
|
| Mothers | 1 | 2020 | 281 | 0.120 |
Why?
|
| Gray Matter | 1 | 2016 | 43 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 54 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2016 | 79 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 111 | 0.120 |
Why?
|
| Recurrence | 3 | 2025 | 665 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 47 | 0.110 |
Why?
|
| Comorbidity | 2 | 2016 | 1122 | 0.110 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 150 | 0.110 |
Why?
|
| Infliximab | 1 | 2015 | 50 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 35 | 0.110 |
Why?
|
| Brain | 3 | 2023 | 1672 | 0.110 |
Why?
|
| Patient Participation | 1 | 2017 | 239 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 198 | 0.110 |
Why?
|
| Interferon beta-1a | 3 | 2020 | 9 | 0.110 |
Why?
|
| Methotrexate | 1 | 2015 | 81 | 0.110 |
Why?
|
| Body Fluids | 1 | 2014 | 21 | 0.110 |
Why?
|
| Research Report | 1 | 2014 | 26 | 0.110 |
Why?
|
| Prevalence | 2 | 2016 | 1454 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2014 | 37 | 0.100 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2014 | 3 | 0.100 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2014 | 4 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 83 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 395 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 155 | 0.100 |
Why?
|
| Hypertrophy | 1 | 2013 | 29 | 0.100 |
Why?
|
| Nucleosomes | 1 | 2015 | 192 | 0.100 |
Why?
|
| Decision Making | 1 | 2017 | 430 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 323 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 316 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5834 | 0.100 |
Why?
|
| Health Personnel | 1 | 2017 | 391 | 0.100 |
Why?
|
| Hydroxybutyrates | 2 | 2025 | 9 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 109 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2012 | 33 | 0.090 |
Why?
|
| Nitriles | 2 | 2025 | 82 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 169 | 0.090 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2012 | 25 | 0.090 |
Why?
|
| Histones | 1 | 2015 | 497 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 663 | 0.090 |
Why?
|
| Chromatin | 1 | 2015 | 643 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 741 | 0.080 |
Why?
|
| Neurons | 1 | 2015 | 935 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 248 | 0.070 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 74 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2500 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2006 | 51 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 961 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1148 | 0.060 |
Why?
|
| Child | 3 | 2020 | 4653 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 449 | 0.050 |
Why?
|
| Acetamides | 1 | 2024 | 17 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 3340 | 0.050 |
Why?
|
| Interferon-beta | 2 | 2014 | 79 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 216 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 435 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 120 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2025 | 747 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2025 | 287 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5682 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 13 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2023 | 84 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 2023 | 39 | 0.050 |
Why?
|
| Plasma | 1 | 2022 | 39 | 0.050 |
Why?
|
| Metabolome | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2024 | 276 | 0.050 |
Why?
|
| Gadolinium | 1 | 2023 | 111 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 114 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 46 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 664 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 137 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2023 | 420 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1012 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 30 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2020 | 115 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 301 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 86 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 42 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 79 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 160 | 0.040 |
Why?
|
| Caspases | 1 | 2020 | 176 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1569 | 0.040 |
Why?
|
| Walking | 1 | 2021 | 248 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 269 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 363 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 617 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 1229 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1060 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 625 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 505 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 87 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 267 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2016 | 62 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1274 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2020 | 352 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 6957 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 170 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 188 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 329 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 691 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2015 | 63 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 106 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 6368 | 0.030 |
Why?
|
| Fetus | 1 | 2015 | 103 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 1718 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 806 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1042 | 0.030 |
Why?
|
| JC Virus | 1 | 2014 | 23 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 268 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 21493 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 31 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 11185 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2014 | 15 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 755 | 0.030 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2014 | 12 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 122 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 147 | 0.030 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 25 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 175 | 0.020 |
Why?
|
| Hippocampus | 1 | 2015 | 277 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 232 | 0.020 |
Why?
|
| Riluzole | 1 | 2012 | 7 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3506 | 0.020 |
Why?
|
| Occupational Therapy | 1 | 2012 | 12 | 0.020 |
Why?
|
| Arm | 1 | 2012 | 45 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 46 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 2401 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 94 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1172 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 80 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 576 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 665 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 230 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 408 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 517 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 911 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 382 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2116 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3779 | 0.020 |
Why?
|
| United States | 1 | 2020 | 8189 | 0.020 |
Why?
|